Otezla patent?

Otezla is the brand name for apremilast, a PDE-4 inhibitor used for psoriasis, psoriatic arthritis, etc. If you’re asking about patents, here’s the quick picture:

- There are multiple patent families tied to apremilast:
- Composition-of-matter patents on the molecule itself (the core apremilast patent).
- Use patents covering treatment methods for inflammatory diseases (psoriasis, psoriatic arthritis, Behçet’s, etc.).
- Additional patents on formulations, salts/solvates, and methods of synthesis.

- Patent term and expiry are jurisdiction-specific:
- Composition patents have terms that typically run about 20 years from the earliest filing date, plus any term adjustments; many such core patents have expired or are nearing expiry in several markets.
- Use and formulation patents, and any continuation patents, can extend protection in some markets.
- Regulatory exclusivities (e.g., data/NCE exclusivity) can also affect market protection independent of patent status.
- In the US, generic entry has occurred in some periods as patents expired or were litigated; in other regions, protection can last longer depending on local patent law.

If you want precise status, I can look up current patent numbers and expiry dates for:
- United States
- European Union (EU/UK)
- Other jurisdictions (e.g., Japan)

Please tell me:
- Which country or region you care about
- Whether you want composition-of-matter patents, use patents, or both

I can then provide the exact patent numbers, their status (active/expired), and approximate expiry dates.